Transasia Bio-Medicals Ltd
The National Medical Devices Policy is expected to help India's medical devices sector market grow to US$ 50 billion by 2030 alongside achieving a 10-12% global market share over the next 25 years.
Established in 1979, Transasia Bio-Medical Ltd. is a leading in-vitro diagnostic company. The company offers products and services across sectors including biochemistry, hematology, coagulation, ESR, immunology, urinalysis, critical care, diabetes management and microbiology. It manufactures blood-analysers and reagents. Transasia is a part of the Erba Mannheim GmbH Group, a Germany-based IVD solution provider. Its products are exported to countries such as Italy, Germany, France, Australia, China, Turkey, USA, Latin America, Africa, Russia, Middle East, SAARC and Asia.
- Completed over 45,000 installations in India.
- Has more than 150 service engineers, 350 sales and marketing team, 14 zonal offices and 350 distributors.
- Has sales in over 100 countries.
Transasia Bio-Medical Ltd. – Customer service of the highest quality
| Year | Milestone |
|---|---|
| 2023 |
In March 2023, Transasia Bio-Medicals Ltd. announced the launch of Made in India clinical chemistry test kits, Erba CRP and Erba HbAic, by Union Minister for Road Transport & Highways, Mr. Nitin Gadkari at its manufacturing facility located in Andhra Pradesh MedTech Zone Ltd, Visakhapatnam. |
| 2022 |
In December 2022, Transasia Bio-Medicals Ltd. announced its collaboration with Andhra Pradesh Medical Services and Infrastructure Development Corporation (APMSIDC) to facilitate the supply of Erba range of fully/semi-automated biochemistry analysers, coagulation analysers, and urine chemistry analysers. The first indigenously-developed RT-PCR kit for testing monkeypox was launched by Transasia at the Andhra Pradesh Medtech Zone (AMTZ) in August, 2022. |
| 2021 |
In March 2021, Transasia Bio-Medical Ltd., a Mumbai-based leading in-vitro diagnostic company announced plans to invest Rs. 150 crore (US$ 21 million) to set up a manufacturing unit at Medical Devices Park in Sultanpur, Telangana. The company plans to make high technology and advanced analysers in the Telangana unit to cater to biochemistry, immunology, hematology, molecular tests, besides Covid, HIV, Dengue and TB tests for both domestic and export markets. |
| 2020 |
Established a manufacturing facility for COVID-19 diagnostic kits in Visakhapatnam, India. Expanded the distribution of ‘ErbaLisa COVID-19 IgG’, the antibody test kits, across 50,000 diagnostic labs in India |
| 2019 |
Launched ‘MX16’, a fully automated molecular testing system. Planned to acquire a manufacturing facility in Brazil as a step to participate in the ‘Make in Brazil’ campaign. Launched its Hematology analysers in India. Entered the Rs. 300 crore (US$ 40.7 million) Indian molecular diagnostic space through the launch of MX 16, a fully automated nucleic acid extractor. Launched ‘Lisa XL’, a processor designed for blood banks with high workload settings. Invested Rs. 50 crore (US$ 6.8 million) to expand the manufacturing facility in Sikkim. |
| 2018 |
Introduced the ‘ErbaQik’ range of rapids to detect Dengue and Malaria. |
Partners
